Thomas McNerney & Partners

Vertiflex Inc., established in 2005 and headquartered in Carlsbad, California, is a medical device company specializing in minimally invasive spinal surgery technologies. The company's primary product is the Superion Interspinous Spacer, a titanium implant designed to treat moderate lumbar spinal stenosis by fitting between the spinous processes in the lumbar spine. This motion-preserving solution offers an indirect decompression system, providing an alternative treatment option for patients with lumbar stenosis who may not require traditional spine surgery. As of June 11, 2019, Vertiflex Inc. operates as a subsidiary of Boston Scientific Corporation.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

SG Biofuels is an integrated bioenergy crop company specializing in the development and production of elite hybrid seeds of Jatropha, a low-cost feedstock for biodiesel, bio-jet fuel, and specialty chemicals. Leveraging the largest and most diverse library of Jatropha genetic material, the company utilizes molecular breeding and biotechnology to optimize its offerings. SG Biofuels combines advanced scientific research with expertise in agronomy and plantation management to capitalize on the potential of Jatropha. The company has received multiple accolades, including recognition as one of the Top 5 Renewable Jet Fuel Supply Chain Companies and one of the Top 50 Companies in Bioenergy for several consecutive years. Additionally, it has been honored with awards for its contributions to feedstock domestication and sustainability within the biofuel sector.

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for orphan diseases, particularly those involving involuntary movement disorders. The company’s pipeline features product candidates aimed at addressing significant unmet medical needs, including hyperkinetic movement disorders such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Auspex Pharmaceuticals specializes in creating deuterated analogs of clinically-validated drugs, enhancing existing therapies across various therapeutic areas, including respiratory disease and inflammation. Through its focused approach, the company seeks to provide effective treatment options for patients suffering from these challenging conditions.

AxioMed LLC is a medical device company based in Malden, Massachusetts, specializing in the design and development of disc replacement devices aimed at alleviating neck pain and restoring normal spinal function for patients suffering from degenerative disc disease. Founded in 2001, the company was previously known as AxioMed Spine Corporation and rebranded in November 2014. AxioMed has developed the Freedom® Lumbar Disc and is also working on a project for cervical disc replacement. The company emphasizes advancing the standard of care beyond traditional fusion techniques and first-generation artificial discs. Guided by CEO Patrick McBrayer and COO James Kuras, AxioMed boasts a team with significant expertise in spinal implants, complemented by a Medical Advisory Panel of surgeons from leading spine centers and universities. The company's facilities encompass product development, testing, clinical and regulatory affairs, and manufacturing.

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for orphan diseases, particularly those involving involuntary movement disorders. The company’s pipeline features product candidates aimed at addressing significant unmet medical needs, including hyperkinetic movement disorders such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Auspex Pharmaceuticals specializes in creating deuterated analogs of clinically-validated drugs, enhancing existing therapies across various therapeutic areas, including respiratory disease and inflammation. Through its focused approach, the company seeks to provide effective treatment options for patients suffering from these challenging conditions.

Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.

Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, founded in 2005. The company is dedicated to developing innovative therapies for the treatment of pruritus and gastrointestinal diseases. Its primary product is Asimadoline, an orally active kappa opioid receptor agonist designed to alleviate itching associated with atopic dermatitis. Additionally, Tioga is focused on treating gastrointestinal conditions, with Asimadoline also aimed at addressing irritable bowel syndrome and functional dyspepsia. This drug candidate is notable for its favorable safety profile, allowing for therapeutic benefits without the typical side effects associated with mu-opioid medications.

SG Biofuels is an integrated bioenergy crop company specializing in the development and production of elite hybrid seeds of Jatropha, a low-cost feedstock for biodiesel, bio-jet fuel, and specialty chemicals. Leveraging the largest and most diverse library of Jatropha genetic material, the company utilizes molecular breeding and biotechnology to optimize its offerings. SG Biofuels combines advanced scientific research with expertise in agronomy and plantation management to capitalize on the potential of Jatropha. The company has received multiple accolades, including recognition as one of the Top 5 Renewable Jet Fuel Supply Chain Companies and one of the Top 50 Companies in Bioenergy for several consecutive years. Additionally, it has been honored with awards for its contributions to feedstock domestication and sustainability within the biofuel sector.

InnoPharma, LLC, founded in 2005 and located in Piscataway, New Jersey, is a privately held pharmaceutical research and development company. The firm specializes in developing complex generic and innovative specialty pharmaceutical and bio-pharmaceutical products, particularly in injectable and ophthalmic dosage forms. InnoPharma boasts a diverse portfolio of products in various stages of development, utilizing advanced formulations such as suspensions, lyophilized products, emulsions, liposomes, micelles, and lipid complexes.

CAS Medical Systems is dedicated to the design and manufacture of innovative, non-invasive technologies and products vital to patient care in the most challenging clinical environments. With a reputation for the highest quality products available in the markets it serves, CASMED products are used by clinicians worldwide.

Vertiflex Inc., established in 2005 and headquartered in Carlsbad, California, is a medical device company specializing in minimally invasive spinal surgery technologies. The company's primary product is the Superion Interspinous Spacer, a titanium implant designed to treat moderate lumbar spinal stenosis by fitting between the spinous processes in the lumbar spine. This motion-preserving solution offers an indirect decompression system, providing an alternative treatment option for patients with lumbar stenosis who may not require traditional spine surgery. As of June 11, 2019, Vertiflex Inc. operates as a subsidiary of Boston Scientific Corporation.

AxioMed LLC is a medical device company based in Malden, Massachusetts, specializing in the design and development of disc replacement devices aimed at alleviating neck pain and restoring normal spinal function for patients suffering from degenerative disc disease. Founded in 2001, the company was previously known as AxioMed Spine Corporation and rebranded in November 2014. AxioMed has developed the Freedom® Lumbar Disc and is also working on a project for cervical disc replacement. The company emphasizes advancing the standard of care beyond traditional fusion techniques and first-generation artificial discs. Guided by CEO Patrick McBrayer and COO James Kuras, AxioMed boasts a team with significant expertise in spinal implants, complemented by a Medical Advisory Panel of surgeons from leading spine centers and universities. The company's facilities encompass product development, testing, clinical and regulatory affairs, and manufacturing.

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for orphan diseases, particularly those involving involuntary movement disorders. The company’s pipeline features product candidates aimed at addressing significant unmet medical needs, including hyperkinetic movement disorders such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Auspex Pharmaceuticals specializes in creating deuterated analogs of clinically-validated drugs, enhancing existing therapies across various therapeutic areas, including respiratory disease and inflammation. Through its focused approach, the company seeks to provide effective treatment options for patients suffering from these challenging conditions.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

NeuroTherapeutics Pharma, Inc., a biopharmaceutical company, develops therapeutics for patients suffering from central nervous system disorders. It focuses on epilepsy, neuropathic, and acute pain disorders of the nervous system. The company was incorporated in 2006 and is based in Chicago, Illinois.

Altair Therapeutics was a biopharmaceutical company that focused on developing therapeutics to treat human respiratory diseases.

Intuity Medical, Inc. is a medical technology company specializing in blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, the company is known for its innovative POGO Automatic Blood Glucose Monitoring System. This system is the first FDA-cleared automatic, one-step blood glucose meter that integrates lancing, blood collection, and analysis into a single cartridge capable of performing ten tests. Intuity Medical aims to provide a convenient and discreet solution for patients who require regular blood glucose testing, enhancing their ability to manage their diabetes effectively. The company was previously known as Rosedale Medical, Inc. until it rebranded in June 2007.

Virdante Pharmaceuticals, established in 2007 and headquartered in Cambridge, Massachusetts, specializes in developing and marketing drugs targeting autoimmune and inflammatory diseases. Its product portfolio comprises antibody and Fc-fusion drugs designed to address these conditions.

Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercial sale of prescription drug products based on dermal drug delivery platforms. It offers HYDRO 40 foam, a dry skin treatment product; tersi foam, a leave-on foam indicated for the treatment of seborrheic dermatitis and tinea versicolor; rinnovi nail system, a prescription nail system that is designed to clean, treat, and protect diseased, damaged, brittle, and ingrown nails; and cleanse and treat, a pad delivery technology system for the treatment of acne. Quinnova Pharmaceuticals, Inc. was founded in 2003 and is based in Newtown, Pennsylvania.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.

Atritech is a private medical technology company based in Minneapolis, Minnesota, founded in 2000. The company specializes in developing minimally invasive technologies aimed at preventing strokes related to atrial fibrillation. Their flagship product, the WATCHMAN Left Atrial Appendage Closure Technology, is designed to offer a permanent alternative to long-term anticoagulation therapy for patients with non-valvular atrial fibrillation who are at risk of stroke. The device works by closing off the left atrial appendage, preventing harmful blood clots from entering the bloodstream and causing strokes or other complications. The WATCHMAN Device has been CE Marked and is available in many markets outside the United States, while it is currently under investigation in the U.S.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients suffering from acute and chronic liver diseases. The company's primary focus is on its lead product, OCR-002, an ammonia scavenger designed to address hyperammonemia through both intravenous and oral formulations. Recently, Ocera completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and potential future development pathways for its therapeutics.

Clarus Therapeutics, Inc. is a specialty pharmaceutical company based in Northbrook, Illinois, that specializes in men's health. Founded in 2003, the company focuses on developing and commercializing oral testosterone replacement therapies in the United States. Its flagship product, JATENZO, is a soft gel formulation of testosterone undecanoate specifically designed for the treatment of men with hypogonadism, a condition characterized by low testosterone levels. JATENZO is notable for being the first and only oral testosterone replacement therapy available in the market. The company also explores additional androgen-based therapies for both men and women, as well as potential treatments for orphan indications, but JATENZO remains its primary source of revenue.

Tranzyme Pharma is a biopharmaceutical company based in North Carolina, specializing in the discovery, development, and commercialization of mechanism-based therapies for gastrointestinal motility disorders. The company focuses on small molecule therapeutics to address both acute and chronic conditions. Its product portfolio includes TZP-101, designed for the treatment of post-operative ileus and severe gastroparesis, and TZP-301, aimed at addressing obesity and metabolic syndrome. Tranzyme Pharma retains worldwide rights for its therapeutic programs, underscoring its commitment to advancing treatment options in the field of gastrointestinal health.

Leptos Biomedical is a company that specializes in developing innovative neuromodulation therapy solutions for chronic obesity. Founded in 2002 and headquartered in Fridley, Minnesota, the company has created a treatment that operates through the electrical activation of a specific nerve within the autonomic nervous system, utilizing a device similar to a pacemaker. This proprietary approach aims to address the complexities of obesity by targeting the underlying neurological factors contributing to the condition.

Softscope Medical Technologies is a company based in Minnetonka, Minnesota, specializing in the development of endoscopic products. Established in 2003, the firm focuses on creating innovative devices that enhance medical procedures, specifically through the development of CROS-enabled technology. This technology is designed to improve the passage of colonoscopes and facilitate small bowel enteroscopy, addressing critical needs in gastrointestinal diagnostics and treatment.

Founded in 1962, Elron Ventures is a venture capital firm specializing in seed and early-stage investments. It focuses on enterprise software, cybersecurity, and medical tech sectors within Israel.

Galil Medical Ltd. specializes in developing cryotherapy solutions aimed at treating various medical conditions across multiple specialties. Founded in 1996 and headquartered in Yokneam, Israel, with additional offices in Arden Hills, Minnesota, the company provides advanced cryosurgical systems that utilize compressed Argon gas to generate sub-zero temperatures for the cryosurgical ablation of both benign and cancerous tumors. Their product lineup includes the Visual-ICE system, which allows for precise control to protect critical anatomy, as well as the SeedNet and Presice systems designed for minimally invasive percutaneous procedures. Galil Medical's offerings extend to ultra-thin needles, thermal sensors, and other accessories that enhance the efficacy of their treatments. Their technologies are utilized in the management of conditions such as kidney, prostate, liver, lung, and breast cancers, among others. The company operates as a subsidiary of BTG plc, reflecting its integration into a broader healthcare framework.

Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercial sale of prescription drug products based on dermal drug delivery platforms. It offers HYDRO 40 foam, a dry skin treatment product; tersi foam, a leave-on foam indicated for the treatment of seborrheic dermatitis and tinea versicolor; rinnovi nail system, a prescription nail system that is designed to clean, treat, and protect diseased, damaged, brittle, and ingrown nails; and cleanse and treat, a pad delivery technology system for the treatment of acne. Quinnova Pharmaceuticals, Inc. was founded in 2003 and is based in Newtown, Pennsylvania.

Solstice Neurosciences is a specialty biopharmaceutical company dedicated to the development, manufacturing, sales, and marketing of biopharmaceutical products. The company's primary offering is Myobloc (rimabotulinumtoxinB) Injection, known as NeuroBloc in select international markets, which is the only botulinum toxin type B available to healthcare professionals and patients worldwide. This injectable solution is specifically designed for the treatment of cervical dystonia, helping to alleviate the severity of abnormal head positions and associated pain. In addition to its product line, Solstice Neurosciences provides comprehensive support services, including reimbursement assistance, product support, and access to medical information. The company also operates MYOBLOC University, an online educational resource aimed at enhancing physician knowledge through innovative learning technologies.

Intuity Medical, Inc. is a medical technology company specializing in blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, the company is known for its innovative POGO Automatic Blood Glucose Monitoring System. This system is the first FDA-cleared automatic, one-step blood glucose meter that integrates lancing, blood collection, and analysis into a single cartridge capable of performing ten tests. Intuity Medical aims to provide a convenient and discreet solution for patients who require regular blood glucose testing, enhancing their ability to manage their diabetes effectively. The company was previously known as Rosedale Medical, Inc. until it rebranded in June 2007.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients suffering from acute and chronic liver diseases. The company's primary focus is on its lead product, OCR-002, an ammonia scavenger designed to address hyperammonemia through both intravenous and oral formulations. Recently, Ocera completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and potential future development pathways for its therapeutics.

Clarus Therapeutics, Inc. is a specialty pharmaceutical company based in Northbrook, Illinois, that specializes in men's health. Founded in 2003, the company focuses on developing and commercializing oral testosterone replacement therapies in the United States. Its flagship product, JATENZO, is a soft gel formulation of testosterone undecanoate specifically designed for the treatment of men with hypogonadism, a condition characterized by low testosterone levels. JATENZO is notable for being the first and only oral testosterone replacement therapy available in the market. The company also explores additional androgen-based therapies for both men and women, as well as potential treatments for orphan indications, but JATENZO remains its primary source of revenue.

Solstice Neurosciences is a specialty biopharmaceutical company dedicated to the development, manufacturing, sales, and marketing of biopharmaceutical products. The company's primary offering is Myobloc (rimabotulinumtoxinB) Injection, known as NeuroBloc in select international markets, which is the only botulinum toxin type B available to healthcare professionals and patients worldwide. This injectable solution is specifically designed for the treatment of cervical dystonia, helping to alleviate the severity of abnormal head positions and associated pain. In addition to its product line, Solstice Neurosciences provides comprehensive support services, including reimbursement assistance, product support, and access to medical information. The company also operates MYOBLOC University, an online educational resource aimed at enhancing physician knowledge through innovative learning technologies.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.

Tranzyme Pharma is a biopharmaceutical company based in North Carolina, specializing in the discovery, development, and commercialization of mechanism-based therapies for gastrointestinal motility disorders. The company focuses on small molecule therapeutics to address both acute and chronic conditions. Its product portfolio includes TZP-101, designed for the treatment of post-operative ileus and severe gastroparesis, and TZP-301, aimed at addressing obesity and metabolic syndrome. Tranzyme Pharma retains worldwide rights for its therapeutic programs, underscoring its commitment to advancing treatment options in the field of gastrointestinal health.

AxioMed LLC is a medical device company based in Malden, Massachusetts, specializing in the design and development of disc replacement devices aimed at alleviating neck pain and restoring normal spinal function for patients suffering from degenerative disc disease. Founded in 2001, the company was previously known as AxioMed Spine Corporation and rebranded in November 2014. AxioMed has developed the Freedom® Lumbar Disc and is also working on a project for cervical disc replacement. The company emphasizes advancing the standard of care beyond traditional fusion techniques and first-generation artificial discs. Guided by CEO Patrick McBrayer and COO James Kuras, AxioMed boasts a team with significant expertise in spinal implants, complemented by a Medical Advisory Panel of surgeons from leading spine centers and universities. The company's facilities encompass product development, testing, clinical and regulatory affairs, and manufacturing.

Founded in 1997 and headquartered in Wellesley, Massachusetts, Coley Pharmaceutical Group is a biopharmaceutical company focused on developing therapeutics that harness the human immune system to combat cancers, asthma and allergy, autoimmune disorders, and enhance vaccine effectiveness. The company's platform specializes in vaccine adjuvant technology and immunomodulatory drug candidates.

Clarus Therapeutics, Inc. is a specialty pharmaceutical company based in Northbrook, Illinois, that specializes in men's health. Founded in 2003, the company focuses on developing and commercializing oral testosterone replacement therapies in the United States. Its flagship product, JATENZO, is a soft gel formulation of testosterone undecanoate specifically designed for the treatment of men with hypogonadism, a condition characterized by low testosterone levels. JATENZO is notable for being the first and only oral testosterone replacement therapy available in the market. The company also explores additional androgen-based therapies for both men and women, as well as potential treatments for orphan indications, but JATENZO remains its primary source of revenue.

Intuity Medical, Inc. is a medical technology company specializing in blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, the company is known for its innovative POGO Automatic Blood Glucose Monitoring System. This system is the first FDA-cleared automatic, one-step blood glucose meter that integrates lancing, blood collection, and analysis into a single cartridge capable of performing ten tests. Intuity Medical aims to provide a convenient and discreet solution for patients who require regular blood glucose testing, enhancing their ability to manage their diabetes effectively. The company was previously known as Rosedale Medical, Inc. until it rebranded in June 2007.

OsteoBiologics is a biotechnology company. It engages in the development and manufacture of bio-absorbable polymeric scaffolds, films, and related instrumentations for the repair and replacement of bone, soft tissue, and articular cartilage. It provides ACTAEON, a tissue evaluation system, which determines the degree and scope of articular cartilage degeneration. It also manufactures custom parts. OsteoBiologics was founded in 1993 and is headquartered in San Antonio, Texas.

Founded in 1997 and headquartered in Wellesley, Massachusetts, Coley Pharmaceutical Group is a biopharmaceutical company focused on developing therapeutics that harness the human immune system to combat cancers, asthma and allergy, autoimmune disorders, and enhance vaccine effectiveness. The company's platform specializes in vaccine adjuvant technology and immunomodulatory drug candidates.